Evidence map›Paper›PMID 37241761›Full record

ArticleMolecules (Basel, Switzerland)2023

Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with

Morteza Abdoli, Alessandro Bonardi, Niccolò Paoletti, Ashok Aspatwar, Seppo Parkkila, Paola Gratteri, Claudiu T Supuran, Raivis Žalubovskis

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Investigation onPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Morteza AbdoliInstitute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, LV-1048 Riga, Latvia.ORCID 0000-0003-1647-4262
Alessandro BonardiNeurofarba Department, Universitàdegli Studi di Firenze, 50019 Florence, Italy.ORCID 0000-0002-5520-740X
Niccolò PaolettiNeurofarba Department, Universitàdegli Studi di Firenze, 50019 Florence, Italy.ORCID 0000-0002-6874-9419
Ashok AspatwarFaculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.ORCID 0000-0002-6938-7835
Seppo ParkkilaFaculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.ORCID 0000-0001-7323-8536
Paola GratteriLaboratory of Molecular Modeling Cheminformatics & QSAR, Neurofarba Department, Università degli Studi di Firenze, 50019 Florence, Italy.ORCID 0000-0002-9137-2509
Claudiu T SupuranNeurofarba Department, Universitàdegli Studi di Firenze, 50019 Florence, Italy.ORCID 0000-0003-4262-0323
Raivis ŽalubovskisInstitute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, LV-1048 Riga, Latvia.ORCID 0000-0002-9471-1342
University of Florence · ITRiga Technical University · LVTampere University · FI

Funding

European Regional Development Fund 1.1.1.2/VIAA/3/19/398
6 · The paper itself

Abstract

A library of structurally diverse

Indexed as

Carbonic AnhydrasesAmidesCarbonic Anhydrase InhibitorsHumansMolecular StructureStructure-Activity RelationshipSulfonamidesAmidesCarbonic Anhydrase InhibitorsCarbonic AnhydrasesSulfonamidesbacterial enzymescarbonic anhydraseinhibitorsin silico studiesMycobacterium tuberculosissulfonamides

Identifiers

PMID37241761
PMCPMC10222120
OpenAlexW4378515190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.